• metastatic/advanced OC (mOC) - 2nd line (L2) 3

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• avelumab based treatment
• avelumab alone
• avelumab plus pegylated liposomal doxorubicin
• Immune checkpoint association
• nivolumab plus ipilimumab

• versus all
• vs chemotherapy
• vs non platinum-based chemotherapy
• vs anthracyclines
• vs doxorubicin
• vs pegylated liposomal doxorubicin
• vs immune chekpoint inhibitors
• vs anti-PD-(L)1
• vs nivolumab based treatment
• vs nivolumab alone

  All patients Age < 65y (younger) Age > 65y Asian type ECOG ⩾ 1 ECOG 0 hemoglobin concentration > 10g/dl PD-L1 < 1% PD-L1 > 1%

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

metastatic/advanced OC (mOC) - 2nd line (L2), avelumab based treatment vs. anti-PD-(L)1, meta-analysis of study results

No data for this selection

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;